OM in the News: Misplacing the Blame for the Baby Formula Shortage

Due to global supply chain disruptions over the past 2 years, Americans are getting used to product shortages, but they were still surprised by the recent shortage of baby formula, putting babies at risk.

As an immediate relief measure, military planes were recently used to transport baby formula from Europe and Australia to the U.S. Also, Abbott Laboratories, closed by the FDA in February, 2022, just resumed production at its Michigan plant. Despite this, Americans learned that this crisis will not end yet.

There is plenty of blame to go around, write Professors Babich (Georgetown U.) and Tang (UCLA) in Industry Week (June 17, 2022). There are many culprits they say, except for one that has been widely blamed: industry concentration, which is an innocent bystander.

The leading suspect is Abbott’s Michigan baby formula plant, which had poor quality control issues for years, but was not shut down by the FDA until Feb., 2022. The crisis would have been less severe had Abbott adopted the Toyota Production System, our topic in Chapter 16, by fixing its own quality issues sooner.

The runner-up suspect is the FDA. Its inaction and lack of urgency dates to 2019 when it was warned about Abbott’s quality issues. The FDA’s bureaucratic inflexibility means that milk formulas sold in Europe are banned in the U.S. because they exceed the FDA’s nutritional standards due to technicalities, like labeling. Its failure to do its own job is one root cause of the shortage.

Then there is the federal Women, Infants, and Children (WIC) program that funds over half of the baby formula purchased nationwide. The WIC contracting process has an unintended outcome of enabling the “approved” state provider to become a near-monopoly of the formula market for that state.

The press blamed the milk formula crisis on industry concentration–too few U.S. manufacturers. Politicians also tagged this as the culprit, as 90% of all production of baby formula is controlled by 4 companies. But industry concentration is a result of economic forces. Milk formula is a staple with stable demand, so there is no incentive for producers to invest in “just-in-case” capacity.

The crisis may continue beyond Abbott’s plant reopening. Once panic buying mentality sets in, it is difficult for consumers to switch back to normal purchasing habits.

Classroom discussion questions:
1. How is this an OM issue?

2. Explain why the WIC program has impacted the shortages.

OM in the News: Why is There a Baby Formula Shortage?

A baby-formula shortage has led to empty store shelves, product restrictions and panic among parents.

Baby formula shortages have left parents scrambling, in some cases driving hours to find stores stocking the particular brands their infants need because of dietary restrictions. Nationwide, 43% of the most popular baby-formula brands were out of stock in the week that began May 1, up from 31% a month earlier. A normal rate is less than 10%.

The products have been in shortage for months partly because of supply-chain issues caused by the pandemic, reports The Wall Street Journal (May 17, 2022). The situation worsened after Abbott, one of the leading formula makers, recalled some products and shut down its plant in Sturgis, Mich., making Similac and other brands.

The FDA said it found a germ called cronobacter, which can be deadly in infants, in the Sturgis plant. Abbott said there isn’t evidence linking its formula products to illnesses resulting in the hospitalizations of 4 infants, including 2 deaths. The CDC also said the strains of bacteria at the plant didn’t match those involved in cases.

Federal prosecutors allege Abbott didn’t comply with conditions and practices designed to ensure the quality and safety of baby store formula, including steps to protect against contamination by bacteria such as cronobacter. Abbott agreed to hire an outside expert to help bring the plant into compliance with FDA rules, and said it could begin formula production again at its Sturgis plant within 2 weeks of the FDA signing off on the facility’s reopening. It would then take 6-8 weeks for products to be available on store shelves.

Meanwhile, rival Enfamil products experienced delays in shipments and transportation earlier in the year as the pandemic continued to disrupt the food supply chains. (The 2 firms are responsible for 80% of U.S. infant formula sales). Many retail chains are continuing to ration supplies by placing strict limits on orders, while others are trying to find substitutes with little success. Abbott said it is bringing products from its factory in Ireland to the U.S. but added that it will take weeks before the Irish plant’s products are on store shelves.

Meanwhile, everyone from frustrated parents to lawmakers on Capitol Hill have called for inquiries into why shortages have been difficult to resolve.

Classroom discussion questions:

  1. What other products are seeing inventory shortages?
  2. How do they differ from the baby formula issues?